Format

Send to

Choose Destination
Nuklearmedizin. 2015;54(5):197-203. doi: 10.3413/Nukmed-0751-15-06.

Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden.

Author information

1
Priv.-Doz. Dr. Matthias Miederer, Department of Nuclear Medicine, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany, Matthias.miederer@unimedizin-mainz.de.

Abstract

In patients with metastasized, castration resistant prostate cancer (mCRPC) treatment with radium-223 (Xofigo) is an attractive therapeutic option. In particular, patients with high tumour load seem to profit from this treatment in regard of survival and quality of live. Aim of this study was to stratify mCRPC patients according to a quantitative imaging marker derived from routine bone scans (EXINI bone) and analyze haematopoietic toxicity of Xofigo in these patients.

PATIENTS, METHODS:

Toxicity and oncologic outcome were investigated in a cohort of 14 patients with high tumour load. Additionally, based on a web survey, experience of toxicity in 41 high tumour load patients in Germany in 2014 was collected.

RESULTS:

In patients with a bone scan index (BSI) greater than 5, significant toxicity occurred in more patients than expected from the ALSYMPCA trial. This was associated with application of fewer cycles. Similar experiences have been made in other centers in Germany. Approximately 7% of these patients will need very long time or will not recover from grade ≥ 3 toxicity.

CONCLUSION:

Close follow-up of haematopoietic indices and, in case of toxicity, early termination of therapy is in particular necessary in late stage disease where limited bone marrow reserve is likely.

KEYWORDS:

Radium-223; Xofigo; bone scan index; haematopoietic toxicity; high tumour load

PMID:
26392087
DOI:
10.3413/Nukmed-0751-15-06
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center